Decreased phosphatidylcholine plasmalogens - A putative novel lipid signature in patients with stable coronary artery disease and acute myocardial infarction. by Sutter, Iryna et al.
Published in final edited form as: Atherosclerosis. 2016 Mar;246:130-40. doi: 10.1016/j.atherosclerosis.2016.01.003
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
7
8
9
9
6
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
Decreased phosphatidylcholine plasmalogens e A putative novel lipid
signature in patients with stable coronary artery disease and acute
myocardial infarction
Iryna Sutter a, b, 1, Roland Klingenberg c, 1, Alaa Othman a, e, Lucia Rohrer a,
Ulf Landmesser b, c, d, Dierik Heg e, Nicolas Rodondi f, Francois Mach g,
Stephan Windecker h, Christian M. Matter b, c, Thomas F. Lüscher b, c,
Arnold von Eckardstein a, b, i, Thorsten Hornemann a, b, i, *
a Institute of Clinical Chemistry, University and University Hospital of Zurich, Zurich, Switzerland
b Competence Center for Integrated Human Physiology, University of Zurich, Zurich, Switzerland
c Department of Cardiology and Cardiovascular Research, University Heart Center, University Hospital Zurich, Zurich, University of Zurich, Switzerland
d Department of Cardiology, Charite Universit€atsmedizin Berlin, Berlin, Germany
e Institute of Social and Preventive Medicine, Clinical Trials Unit, University of Bern, Bern, Switzerland
f Department of Internal Medicine, University Hospital Bern, Bern, Switzerland
g Cardiology, University Hospital Geneva, Switzerland
h Cardiovascular Center, University Hospital Bern, Switzerland
i Competence Center for Systems Physiology and Metabolic Diseases, ETH Zurich and University of Zurich, Zurich, SwitzerlandKeywords:
Glycerophospholipids
Sphingolipids
Coronary artery disease
Acute myocardial infarction* Corresponding author. Inst. for Clinical Chemistr
Raemistrasse 100, CH-8091, Zurich, Switzerland.
E-mail address: thorsten.hornemann@usz.ch (T. H
1 Both authors contributed equally.a b s t r a c t
Objective: Glycerophospholipids and sphingolipids are structurally heterogeneous due to differences in
the O- and N-linked fatty acids and head groups. Sphingolipids also show a heterogeneity in their
sphingoid base composition which up to now has been little appreciated. The aim of this study was to
investigate the association of certain glycerophospholipid and sphingolipid species with stable coronary
artery disease (CAD) and acute myocardial infarction (AMI).
Methods: The lipid profile in plasma from patients with stable CAD (n ¼ 18) or AMI (n ¼ 17) was
compared to healthy subjects (n ¼ 14). Sixty five glycerophospholipid and sphingolipid species were
quantified by LC-MS. The relative distribution of these lipids into lipoprotein fractions was analyzed.
Results: In the CAD cohort, 45 glycerophospholipid and sphingolipid species were significantly lower
compared to healthy controls. In the AMI group, 42 glycerophospholipid and sphingolipid species were
reduced. Four PC plasmalogens (PC33:1, PC33:2, PC33:3 and PC35:3) showed the most significant dif-
ference. Out of eleven analyzed sphingoid bases, four were lower in the CAD and six in the AMI group.
Sphingosine-1-phosphate (S1P) levels were reduced in the AMI group whereas an atypical C16:1 S1P was
lower in both groups. Phosphatidylcholine and sphingomyelin species were exclusively present in li-
poprotein particles, whereas lysophosphatidylcholines were mainly found in the lipoprotein-free frac-
tion. The observed differences were not explained by the use of statins as confirmed in a second,
independent cohort.
Conclusions: Reduced levels of four PC plasmalogens (PC33:1, PC33:2, PC33:3 and PC35:3) were iden-
tified as a putatively novel lipid signature for CAD and AMI.y, University Hospital Zurich,
ornemann).1. Introduction
Coronary artery disease (CAD) is a major cause of death and
morbidity in the western world [1]. CAD is caused by the gradual
development of atherosclerotic plaques in the arterial wall. A
rupture or erosion of plaques with subsequent total occlusion of an
Published in final edited form as: Atherosclerosis. 2016 Mar;246:130-40. doi: 10.1016/j.atherosclerosis.2016.01.003epicardial coronary artery may lead to acute myocardial infarction
(AMI) [2,3]. Recent data suggest that beyond established lipids risk
factors like cholesterol and triacylglycerols also glycer-
ophospholipids and sphingolipids contribute to atherogenesis [4,5].
Plasma glycerophospholipids and sphingolipids are mainly associ-
ated with lipoprotein particles [6e8] and form a lipid monolayer
around the hydrophobic core of triacylglycerols and cholesteryl
esters. Prior work identified distinct lipid profiles of plasma, serum
or lipoprotein particles in patients with CAD [9e13]. Hundreds of
different glycerophospholipid and sphingolipid species were
identified in plasma lipoproteins and atherosclerotic plaques
[14,15]. In particular sphingolipids are structurally diverse because
of a multiplicity in O-linked head groups and N-linked fatty acids.
Sphingolipids also show a significant heterogeneity in the sphin-
goid base composition which yet has been only little appreciated.
Sphingolipid de-novo formation is initiated by the conjugation of L-
serine and acyl-CoA, a reaction catalyzed by the enzyme serine
palmitoyltransferase (SPT). Sphingoid bases, the product of this
reaction are the common structural feature for all sphingolipid
species. The most abundant sphingoid bases in plasma is C18
sphingosine, but SPT can also form other sphingoid bases in the
range of C14eC20 [16]. Under certain conditions, SPT also metabo-
lizes L-alanine and glycine which forms an atypical category of 1-
deoxysphingolipids (1-deoxySLs) [17,18] which were shown to be
elevated in several metabolic conditions.
The aim of this study was to identify novel plasma lipid signa-
tures for patients with CAD or AMI.
2. Materials and methods
2.1. Patients
Healthy subjects (n ¼ 14) were recruited from the local blood
bank. Exclusion criteria were the use of cardiovascular medication,
positive cardiovascular family history, smoking (including cessa-
tion of smokingwithin 2 years prior to study enrollment), history of
hypertension, elevated total cholesterol (5.0 mmol/L),
BMI > 30 kg/m2, history of diabetes mellitus, evidence of relevant
vascular or structural heart disease and/or a reduced LVEF (<55%)
on echocardiogramm. The stable CAD group (n ¼ 18) was selected
from patients with angiographically documented coronary artery
stenosis 50%. Exclusion criteria comprised an ACS within the
preceding 6 months, systemic infectious, inflammatory or auto-
immune disease, known severe renal dysfunction (serum creati-
nine >220 mmol/L), known severe hepatic dysfunction (3x ULN for
LFTs), neoplasm or other life-threatening disease with a life ex-
pectancy less than one year, extended surgery in the preceding 3
months and/or evidence of vascular or structural heart disease and/
or a reduced systolic LV function on echocardiogram or left ven-
tricular angiogram.
Patients with AMI (n¼ 17) were selected from the Inflammation
in Acute Coronary Syndromes cohort (SPUM-ACS, NCT01000701).
SPUM-ACS inclusion criteria comprised both genders (aged 18
years) presenting within five days (preferably within 72 h) after
onset of chest pain and a main diagnosis of STEMI, NSTEMI or un-
stable angina as described previously [19].
All patients gave written informed consent and the study was
conducted with approval from the local ethics committee (EK-
1680).
2.2. Sampling of plasma
Blood was drawn from the antecubital vein in healthy subjects
and from the femoral/radial artery at the time of diagnostic coro-
nary angiography in patients with CAD or AMI, respectively.Samples were centrifuged at 2700 g for 10 min at room tempera-
ture to obtain plasma, frozen and stored in aliquots at 80 C until
serial measurement (no prior freeze-thaw cycles). To avoid inter-
assay differences all samples were extracted and analyzed in a
single batch. The person who performed the analysis was blinded
to the patient's data by the use of numbered ID codes.
2.3. Clinical chemistry
Plasma concentrations or activities of total cholesterol, tri-
glycerides, LDL-C and HDL-C, glucose, creatine kinase, CK-MB, and
troponin levels were determined by photometric tests or immu-
noassay by using the Cobas 8000 autoanalyzer from Roche di-
agnostics (Rotkreuz, Switzerland).
2.4. Isolation of lipoproteins
Human lipoprotein fractions and the lipoprotein-free fraction
(LFF) were isolated from plasma of three healthy blood donors by
stepwise ultracentrifugation, as described previously [20]. Purity of
lipoprotein fractions was confirmed by SDS-PAGE and Coomassie
Blue staining.
2.5. Analysis of plasma glycerophospholipids and sphingolipids
Six lipid classes including phosphatidylglycerols (PGs), phos-
phatidic acids (PAs), phosphatidylethanolamines (PEs), phosphati-
dylcholines (PCs), sphingomyelins (SMs) and ceramides/
hexosylceramides (Cers/HexCers) were analyzed. Lipids were
quantified in relation to internal standards (200 ng) including
PG(17:0/17:0), LPG(17:1/0:0), PA(14:0/14:0), LPA(17:0/0:0), PE(14:0/
14:0), LPE(17:1/0:0), PC(14:0/14:0), PC(24:0/24:0), LPC(17:0/0:0),
SM (d18:1/12:0) and Cer(d18:1/17:0) (Avanti Polar Lipids, Alabaster,
AL, USA). 20 ml plasma was extracted with 375 ml of methanol/
chloroform (2:1 v/v). After vortexing, 100 ml water and 125 ml
chloroform were added, agitated (15 min), centrifuged (16,100 g
for 5 min at 25 C) and the lower phase collected. Again 250 ml
chloroform was added, agitated (15 min) and centrifuged. The
lower phases were combined and evaporated under a stream of
nitrogen. Analysis was done on a TSQ Quantum Access triple
quadrupole connected to a Rheos 2200 pump. Separationwas done
on a diol silica-based column (QS Uptisphere 6 OH, 150  2.1 mm,
5 mm). Mobile phase (A) was hexane/isopropanol/water (70:30:2 v/
v) including 15 mM NH4COOH; and (B) isopropanol/water (50:2 v/
v) including 15 mM NH4COOH at a flow rate of 0.35 ml/min.
Gradient was 0e7 min A/B (%) 80/20; 8e10 min A/B (%) 60/40,
11e23 min A/B (%) 40/60 and 25e30 min A/B (%) 80/20. Dried
material was reconstituted in 200 ml of mobile phases A (80%) and B
(20%) an injected (10 ml) into the LC-MS. Neutral loss and precursor
scans were used to detect specific glycerophospholipids and
sphingolipids. A neutral loss scan of m/z 115 and 189 from
[M þ NH4]þ ions was used for the analysis of PA and PG lipids.
Precursor ion scan ofm/z 184, specific for phosphocholine was used
for PC, SM and LPC lipids. Neutral loss scan of m/z 141 was used for
PEs and precursor scanning of m/z 264 was applied for Cer and
HexCer species. Data were analyzed in Xcalibur (version 2.0.6,
Thermo Scientific). Identification of molecular species was per-
formed by lipid mass spectrum analysis software (LIMSA) [21].
The assignment of glycerophospholipids includes total numbers
of carbons and double bonds in two acyl chains. The SM assignment
comprises total numbers of carbons and double bonds in the
sphingoid base and N-linked fatty acid. Hexosylceramide species
include isomeric glucosyl- and galactosylceramides. For identified
Cers and HexCers, molecular structures are reported. Quantification
was done in relation to the respective internal standards.
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Sphingosine-1-phosphates (S1Ps) in plasma samples were
determined by LC-MS as described previously [22]. Concentrations
of S1P species were measured in 25 ml of plasma spiked with
10 pmol internal standard 18:1-D7S1P (Avanti Polar Lipids,
Alabaster, AL, USA). Analysis of S1P species included the quantifi-
cation of 16:1-S1P, 17:1-S1P, 18:1-S1P and 18:0-S1P lipids.
2.7. Quantification of sphingoid bases
The profile of 11 plasma sphingoid bases was analyzed by LC-MS
as described earlier [23]. d7-sphingosine (D7SO) and d7-
sphinganine (D7SA) (200 pmol each) were used as internal stan-
dards (Avanti Polar Lipids, Alabaster, AL, USA).
2.8. Statistical analysis
Statistical analysis was performed using SPSS, version 19 (IBM
Corporation, Somers NY, USA). Normality of the data was deter-
mined by using theKolmogorov-Smirnov test. For variables which
did not show a normal distribution, univariate statistics was done
using Kruskal-Wallis and the Mann-Whitney U tests. Categorical
variables were compared using the Chi-square test. Spearman rank
tests were used to describe the correlations of plasma glycer-
ophospholipids and sphingolipids with total cholesterol, LDL-C and
HDL-C levels. The p values were adjusted for multiple comparisons
by applying the Benjamini-Hochberg procedure [24]. Adjusted
(adj.) p values of <0.05 were considered statistically significant.
3. Results
3.1. Patient characteristics
Here we compared the plasma lipid profile between healthy
subjects and patients with stable CAD (n ¼ 18) or AMI (n ¼ 17). The
age of the patients ranged between 43 and 77 years. On average,
healthy subjects (56.4 ± 7.5 years) were ten and patients with CAD
(61.3 ± 8.3 years) five years younger than patients with AMI
(66.8 ± 10.0 years). Features of acute myocardial infarction,Table 1
Clinical characteristics of the study population. Values are means ± SD or percentages for
Wallis (multiple group comparisons), and by theMann-Whitney U test (two group compar
p values were adjusted for multiple testing by using the Benjamini-Hochberg procedu
discharge).
Characteristics Healthy subjects (n ¼ 14) CAD (n ¼ 18) AMI
Mean ± SD Mean ± SD Mea
Age (years) 56.4 ± 7.5 61.3 ± 8.3 66.8
Gender, female (%) 36 22 18
Smoking (%) 0 75 56
Statin treatment (%) 0 100 100
BMI (kg/m2) 24.5 ± 3.48 27.85 ± 3.52 26.4
Systolic blood pressure (mmHg) 119.36 ± 13.99 129.89 ± 16.52 128
Diastolic blood pressure (mmHg) 71.36 ± 9.79 76.50 ± 10.76 76.0
Glucose (mmol/l) 5.18 ± 0.44 5.43 ± 0.56 6.32
Total cholesterol (mmol/l) 5.78 ± 0.97 4.05 ± 0.89 3.84
LDL-C (mmol/l) 3.53 ± 0.83 2.39 ± 0.76 2.28
HDL-C (mmol/l) 1.83 ± 0.42 1.18 ± 0.32 1.22
Triglycerides (mmol/l) 0.98 ± 0.43 1.07 ± 0.46 0.75
NT-proBNP (ng/L) 41.21 ± 35.36 140.22 ± 108.47 817
Creatine kinase (mg/l) 136.18 ± 76.96 119.65 ± 42.47 130
CK-MB (mg/l)* 11.60 ± 3.47 10.86 ± 5.41 141
Troponin T (ug/l)* 0.01 ± 0 0.03 ± 0.03 2.65
Abbreviations: AMI, acute myocardial infarction; CAD, coronary artery disease; CK-M
cholesterol; LDL-C, low-density lipoprotein cholesterol; NT-proBNP, N-terminal pro-B-tyincluding elevated levels of troponin T, NT-proBNP, creatine kinase
and CK-MB were higher in the AMI group (Table 1). Prevalence of
smoking was significantly higher in CAD and AMI group. Average
BMI was higher in patients with CAD compared to healthy subjects.
LDL-C and total cholesterol levels were lower in patients with
stable CAD and AMI due to statin treatment.3.2. Plasma lipidome e alterations in patients with CAD and AMI
Sixty-five lipid species were analyzed in this study. As statin use
was significantly higher in the CAD and AMI group (Table 1) we first
tested for an influence of statins on the analyzed lipids species by
comparing CAD patients with and without statin treatment
(Table 2). No significant differences for the analyzed glycer-
ophospholipid and sphingolipid species were observed between
the two groups.
Next we compared the same lipid profile between healthy
subjects and patients with CAD and AMI. Univariate statistics
revealed significant changes in the plasma lipid profile for patients
with stable CAD and AMI compared to healthy individuals (Table 3).
The total levels of PC, LPC, PE, SM and Cer/HexCer lipids were
generally lower in patients with stable CAD and AMI compared to
healthy subjects (Table 3). Total Cer and HexCer were further
reduced in patients with AMI compared to the CAD group.
Comparing the individual lipid species we observed differences in
45 molecular species (19 PCs, 4 LPCs, 5 PEs, 12 SMs and 5 Cers/
HexCers) for the CAD and differences in 42 lipid species (15 PCs, 2
LPCs, 9 PEs, 11 SMs and 5 Cers/HexCers) for the AMI group in
comparison to healthy subjects (Table 3).
Sphingoid bases are the shared structural component for all
sphingolipids. C18 sphingosine (d18:1) is typically the most abun-
dant sphingoid base in plasma although a wide range of other
sphingoid bases can be found too. For sphingoid base analysis, total
sphingolipids were extracted from plasma samples and hydrolyzed
to remove the conjugated N-acyl chain and head groups. It is
important to note that the here reported sphingoid base concen-
trations refer to the total levels of a given sphingoid base in plasma
irrespective of the sphingolipid specie where it was originally
contained (e.g Cer, hexCer, SM etc). In the CAD and AMI group, we
observe lower plasma levels for C17SO, C18SO, C18SA and C18SAdienescale or categorical variables. Statistical significance was determined by the Kruskal-
isons). p values for the categorical variables were calculated by using Chi-square test.
re. (Significant results are marked bold,* variables were measured before hospital
(n ¼ 17) Kruskal-Wallis, adj. p Values Mann-Whitney U, adj. p Values
n ± SD H vs CAD H vs ACS CAD vs ACS
± 10.0 0.005 0.164 0.004 0.084
0.488 0.492 0.347 0.784
0.001 <0.001 0.04 0.352
<0.001 <0.001 <0.001 0.649
5 ± 3.15 0.03 0.035 0.084 0.22
.59 ± 19.11 0.248 0.163 0.232 0.92
6 ± 11.27 0.267 0.22 0.215 0.981
± 0.98 0.005 0.362 0.006 0.018
± 1.00 <0.001 <0.001 <0.001 0.448
± 0.92 0.001 0.004 0.004 0.609
± 0.28 <0.001 <0.001 0.001 0.618
± 0.53 0.099 0.738 0.132 0.081
.88 ± 1013.81 <0.001 0.006 <0.001 0.026
4.76 ± 828.56 <0.001 0.981 <0.001 <0.001
.49 ± 103.43 <0.001 0.558 <0.001 <0.001
± 1.89 <0.001 0.013 <0.001 <0.001
B, creatine kinase-MB; BMI, body mass index; HDL-C, high-density lipoprotein
pe natriuretic peptide.
Table 2
Plasma glycerophospholipids and sphingolipids in statin-treated and non-treated patients with CAD. Statistical significance was calculated by the Mann-Whitney U test. The
p values were adjusted for multiple testing using the Benjamini-Hochberg procedure. Total lipids are presented for phosphatidylcholines (PCs), lysophosphatidylcholines
(LPCs), phosphatidylethanolamines (PEs), phosphatidylglycerols (PGs), sphingomyelins (SMs), ceramide/hexosylceramides (Cers/HexCers). Glycerophospholipids are shown
with total numbers of carbons and double bounds. SM species are summarized by numbers of carbons and double bounds in sphingoid base and N-linked fatty acid.
Sphingosine-1-phosphate (S1P) species include numbers of carbons and double bonds in sphingoid base. HexCer species include isobaric glucosyl- and galactosylceramides.
(n.d. - not detected).
Lipids (mM) CAD statin-treated (n ¼ 10) CAD statin-untreated (n ¼ 10) Mann-Whitney U, adj. p values
Median(Min; Max) Median(Min; Max) CAD statin-treated vs
CAD statin-untreated
Total PC 795.3(614.8; 895.6) 823.6(692.2; 1195.8) 0.649
PC32:0 5.6(3.1; 7.8) 6.8(4.6; 9.5) 0.406
PC32:1 8.5(3; 15.5) 11.6(3.6; 15.4) 0.649
PC33:1 5.3(2.4; 9) 6.7(4.3; 9.3) 0.402
PC33:2 5.4(3.3; 12.3) 7(3.7; 10.5) 0.402
PC33:3 2.8(1.4; 5.9) 3.5(2.5; 7.8) 0.48
PC34:0 7.5(4.4; 11.7) 9.1(5; 11.6) 0.553
PC34:1 87.4(50; 126.5) 112.9(77.4; 152.8) 0.402
PC34:2 152.2(88; 222.1) 174.5(115.6; 297.4) 0.649
PC34:3 6.3(4.3; 9) 7.3(3.9; 10.6) 0.498
PC35:1 2.7(1; 3.5) 3.8(1.9; 5.5) 0.402
PC35:2 5.8(3.5; 6.3) 6.9(4.7; 11.2) 0.465
PC35:3 4.4(2.3; 8) 5.6(3.9; 9.7) 0.429
PC35:4 11.6(8.9; 17.9) 14.9(8.6; 19.3) 0.48
PC35:5 7.8(4.8; 15.3) 9.3(6.8; 12.9) 0.649
PC36:0 4(2.8; 5.7) 3.9(1.8; 6.6) 0.837
PC36:1 22.6(16.8; 31.2) 31.1(18.9; 42.7) 0.402
PC36:2 81.8(56.3; 115.2) 86.4(67.2; 144.3) 0.702
PC36:3 53(41.6; 68.1) 54.9(38; 77.5) 0.869
PC36:4 81.8(47.4; 103.9) 74.5(53.9; 120.8) 0.869
PC36:5 8.6(2; 19.8) 9.9(6.2; 15.6) 0.759
PC37:4 10.3(7.2; 15.9) 11.6(7.3; 14.2) 0.649
PC37:5 12.5(7.8; 16.4) 15.2(9.3; 21.6) 0.465
PC37:6 5.3(4.1; 9) 6.7(4.6; 9.9) 0.406
PC38:3 27.7(18.9; 37.1) 24.1(20.4; 43.3) 0.9
PC38:4 65.1(28.3; 75.7) 55.8(37.7; 101.3) 0.735
PC38:5 23.3(12.3; 30) 21.8(17.3; 27) 0.735
PC38:6 24.9(10.4; 34.5) 24(15.5; 31.5) 0.9
PC40:5 6.1(4.3; 7.4) 6.1(4.5; 9.6) 0.848
PC40:6 10.6(5; 14.1) 10.3(5.7; 15.7) 0.869
Total LPC 123.6(80.5; 154.7) 129.3(88.7; 179.2) 0.735
LPC16:0 67.4(44.8; 77.5) 75.2(53; 96.7) 0.48
LPC18:0 21.3(14.8; 27.7) 25.8(12; 34) 0.649
LPC18:1 14.7(8.8; 20.4) 14(9; 26.2) 0.702
LPC18:2 20.6(8.8; 37.9) 15.1(9.1; 32.3) 0.649
Total PE 14.2(6.3; 40.2) 16.3(8.2; 70) 0.759
PE34:2 0.9(0.2; 3.3) 1.6(0.3; 5.5) 0.649
PE35:2 0.1(0.03; 0.3) 0.3(0.1; 0.6) 0.402
PE36:4 1.3(0.8; 3.4) 1.7(0.5; 6.2) 0.837
PE36:3 0.8(0.1; 1.7) 0.9(0.2; 4.5) 0.759
PE36:2 2.8(0.7; 8.7) 3.5(0.6; 20.6) 0.759
PE36:1 0.6(0.1; 2.5) 0.8(0.1; 5.3) 0.56
PE37:5 0.4(0.03; 0.5) 0.8(0.2; 1.3) 0.402
PE37:4 0.2(0.1; 0.6) 0.2(0.1; 0.5) 0.848
PE38:6 2(0.5; 7.3) 2.2(0.9; 7.4) 0.702
PE38:5 1(0.6; 2.5) 1.3(0.5; 3.2) 0.804
PE38:4 3.9(1.9; 10.4) 4.4(2.1; 15.6) 0.804
Total PG 0.4(0.2; 0.7) 0.4(0.2; 1.7) 0.94
Total PA n.d. n.d. e
Total SM 502.6(283.2; 628) 560.4(428.8; 702) 0.465
SM32:1 11.1(5.5; 18) 14.6(12; 17.7) 0.402
SM34:0 4(1.1; 5) 4.4(1.5; 6.1) 0.694
SM34:1 100.3(62.1; 136) 115.8(86.2; 161.1) 0.402
SM34:2 14.6(8.5; 22.8) 16.2(12.5; 28.3) 0.498
SM36:1 29.9(15.6; 42) 26.3(22.9; 46.6) 0.94
SM36:2 10.3(7.1; 14.3) 11.4(8.1; 16.8) 0.735
SM38:1 26.7(15; 32.1) 29.4(21.5; 36.6) 0.465
SM39:1 9.9(5.2; 16.7) 10.9(6.9; 15) 0.702
SM39:2 1.3(0.8; 2.3) 1.5(0.7; 1.9) 0.694
SM40:1 53.7(28.3; 66) 67.5(42.8; 95) 0.406
SM40:2 31.9(19; 39.5) 38.9(24.7; 49.5) 0.402
SM41:1 26.2(11.1; 38) 34.7(23.7; 42.7) 0.406
SM41:2 17.1(8.8; 25.6) 21.9(14.3; 31.2) 0.618
SM42:1 43(20.7; 52.3) 48.7(33.7; 75.6) 0.649
SM42:2 74.3(53.1; 113.7) 88.1(68.1; 123.5) 0.56
(continued on next page)
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Table 2 (continued )
Lipids (mM) CAD statin-treated (n ¼ 10) CAD statin-untreated (n ¼ 10) Mann-Whitney U, adj. p values
Median(Min; Max) Median(Min; Max) CAD statin-treated vs
CAD statin-untreated
SM42:3 28.9(21.3; 39.5) 34(19.9; 48.5) 0.702
Total Cer/HexCer 7.6(4.6; 13.4) 9.4(6.5; 21.5) 0.465
Cer(d18:1/24:0) 2.3(1.5; 3.5) 2.6(1.4; 5.4) 0.837
HexCer(d18:1/22:0) 1.4(0.8; 2.1) 1.3(0.5; 5.3) 0.848
HexCer(d18:1/23:0) 0.6(0.1; 1.5) 1.4(0.6; 2.4) 0.402
HexCer(d18:1/24:0) 2(1.1; 3.7) 2.8(1.4; 6.5) 0.429
HexCer(d18:1/24:1) 1.2(0.6; 2.6) 1.7(0.7; 2.9) 0.649
S1P species
16:1-S1P 0.1(0.07; 0.15) 0.11(0.07; 0.13) 0.649
17:1-S1P n.d. n.d. e
18:1-S1P 0.45(0.39; 0.64) 0.55(0.51; 0.78) 0.402
18:0-S1P 0.08(0.04; 0.15) 0.06(0.03; 0.1) 0.649
Sphingoid bases of sphingolipids
C16SO 21.96(10.47; 29.5) 23.45(13.69; 27.98) 0.735
C16SA 0.56(0.25; 0.99) 0.55(0.27; 0.8) 0.9
C17SO 9.09(4.43; 10.95) 10.31(6.92; 14.97) 0.406
C18SO 89.08(57.3; 122.08) 112.52(79.23; 140.89) 0.498
C18SA 3.29(1.4; 5.36) 3.35(1.85; 6.49) 0.848
C18SAdiene 34.81(24.08; 46.54) 41.76(25.29; 51.8) 0.402
C19SO 3.56(1.71; 6.75) 3.34(1.73; 4.68) 0.869
C20SO 0.23(0.2; 0.37) 0.22(0.18; 0.34) 0.735
C20SA 0.04(0.02; 0.06) 0.04(0.02; 0.06) 0.848
doxSO 0.18(0.09; 0.39) 0.18(0.04; 0.4) 0.735
doxSA 0.09(0.04; 0.18) 0.09(0.02; 0.17) 0.735
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between patients with CAD and AMI (Table 3). Plasma levels of
C16SO and C16SA were significantly lower in patients with AMI
compared to healthy controls (Table 3). 1-Deoxysphingoid bases
were not significantly altered between the groups.
The analysis of S1P species showed the presence of canonical
18:1-S1P but also of other S1P species, including 16:1-S1P, 17:1-S1P
and 18:0-S1P. Canonical (18:1) S1P was lower in patients with AMI
compared to healthy individuals (Table 3) whereas an atypical
16:1-S1P was lower in both groups (Table 3). Also 17:1-S1P was
detectable but levels were below the limit of quantification
(0.04 mM).
For further analysis, lipid and clinical data were arranged as
volcano plots, showing the relative difference (x-axes) versus sig-
nificance (y-axes). The analyzed lipid species were divided into four
groups: 1. glycerophospholipids including even-chain PCs, PEs,
LPCs and PGs; 2. glycerophospholipids including odd-chain PCs; 3.
sphingolipids including SMs, Cers/HexCers, S1Ps and sphingoid
bases and 4. clinical measures. Comparisons of healthy subjects vs.
patients with CAD are shown in Fig. 1A, comparisons of healthy
subjects vs. patients with AMI in Fig.1B, and comparisons of CAD vs.
AMI in Fig. 1C. The analysis revealed four odd-chain PC species
(PC33:1, PC33:2, PC33:3 and PC35:3) to be the most significantly
lowered species in patients with CAD compared to healthy subjects
(Fig. 1A). The same odd-chain PC species were found to be lowered
in the AMI group (Fig. 1B). Comparing CAD and AMI did not reveal
differences in the lipid species but differences in some clinical
variables including troponin, creatine kinase and CK-MB (Fig. 1C).3.3. Structural analysis identifies odd-chain phosphatidylcholines
as PC plasmalogens
The four identified odd-chain PC species (PC33:1, PC33:2,
PC33:3 and PC35:3) could be either PCs with an odd number of
carbons or PC plasmalogens with a vinyl-ether bond at the sn-1
position of the glycerol backbone. Comparing the MS/MS frag-
mentation pattern of these species to a commercial standard we
already identified PC35:3 as a PC(P-18:0/18:2) plasmalogen in adifferent study [13]. A similar structural analysis of the PC33:1,
PC33:2 and PC33:3 species confirmed them as plasmalogens
PC(P-18:0/16:0), PC(P-16:0/18:1) and PC(P-16:0/18:2), respectively.
The identity of other odd-chain PCs species in the dataset was not
further investigated.
3.4. Plasma glycerophospholipids and sphingolipids correlate with
cholesterol levels
Most of the identified glycerophospholipids and sphingolipids
showed a significant correlation with total cholesterol and LDL-C
(Fig. 2). Correlation with HDL-C was also seen for most species
but less pronounced. Among all glycerophospholipid and sphin-
golipid species, PC33:1, PC33:2, PC33:3 and PC35:3 showed the
strongest correlation with HDL-C (r ¼ 0.81, r ¼ 0.71, r ¼ 0.75 and
r ¼ 0.68, respectively). Furthermore, total cholesterol and LDL-C
correlated strongly with the sphingoid bases C18SO (r ¼ 0.93 and
r ¼ 0.86, respectively) and C17SO (r ¼ 0.85 and r ¼ 0.81, respec-
tively). Saturated LPC species correlatedmorewith total cholesterol
and LDL-C than with HDL-C.
3.5. Glycerophospholipid and sphingolipid levels in the lipoprotein
fractions
Because of the strong correlations between the individual li-
poproteins and plasma glycerophospholipids and sphingolipid
species, we analyzed the distribution of these lipids across the
major lipoprotein fractions. Lipoproteins were isolated from plasma
of three healthy volunteers and the lipid profile analyzed in Chy-
lomicrons/VLDL, LDL, HDL and in the lipoprotein-free fraction (LFF).
Species for PC, SM and LPC were detected in all plasma lipoprotein
fractions. PE and Cer/HexCer species were also present in lipopro-
teins, but at levels below the limit of quantification. Neither PG nor
PA lipids were identified in the lipoprotein or LFF fractions.
The relative percentages of total PC, SM and LPC lipids in the
individual lipoprotein fractions are shown in Fig. 3AeC. The per-
centages of the individual PC, SM and LPC species relative to the
total concentration of a given species in all lipoprotein fractions is
Table 3
Comparison of plasma glycerophospholipids and sphingolipids in healthy subjects and patients with CAD and AMI (medianwith ranges). Statistical significance was calculated
by Kruskal-Wallis andMann-Whitney U. Statistically significant results are indicated in bold. p values were adjusted formultiple testing by the Benjamini-Hochberg procedure.
(AMI acute myocardial infarction; CAD, coronary artery disease; n.d., not detected).
Lipids, mmol/l Healthy subjects (n ¼ 14) CAD (n ¼ 18) AMI (n ¼ 17) Kruskal-Wallis, adj. p values Mann-Whitney U, adj. p values
Median(Min; Max) Median(Min; Max) Median(Min; Max) H vs CAD H vs ACS CAD vs ACS
Total PC 829.3(692.3; 974.1) 725.6(522.7; 793.4) 670.4(595.9; 868.8) <0.001 0.002 0.001 0.38
PC32:0 6.8(5; 9.3) 5(3.3; 6.8) 5.6(3.5; 7.9) 0.002 0.002 0.02 0.314
PC32:1 9(4.9; 18.4) 6.2(3.2; 12) 7.3(4.2; 16.6) 0.094 0.05 0.2 0.697
PC33:1 7.7(7; 11.7) 5.5(2.5; 6.7) 5.8(3.9; 7.9) <0.001 <0.001 0.001 0.584
PC33:2 10.1(6.7; 16) 5.9(2.6; 7.3) 6.4(4.3; 8.8) <0.001 <0.001 0.001 0.314
PC33:3 5.6(3.6; 10.7) 2.8(1.7; 4.2) 3.2(1.6; 4.7) <0.001 <0.001 <0.001 0.584
PC34:0 9.3(6.3; 12.7) 7.1(4.3; 10.5) 7.4(5.4; 9.2) 0.004 0.015 0.002 0.877
PC34:1 92.6(74.9; 122.2) 76.2(42; 101.3) 81.7(51.7; 101.2) 0.043 0.026 0.108 0.681
PC34:2 187.8(156.6; 226.7) 135.9(72.2; 181.7) 129.5(98; 150.1) <0.001 <0.001 <0.001 0.471
PC34:3 8.7(5.1; 9.7) 5.5(3.6; 8.1) 4.5(3.2; 6.8) <0.001 0.002 0.001 0.391
PC35:1 10.3(8; 20.6) 7.4(3.5; 13.1) 7.5(5.8; 12.3) 0.004 0.006 0.006 0.863
PC35:2 8.1(7; 11.4) 6.3(2.9; 8.8) 5.9(4.2; 9.3) <0.001 0.001 0.002 0.681
PC35:3 7.5(6; 11) 5.1(2.3; 7.4) 5.1(2.7; 6.9) <0.001 <0.001 <0.001 0.932
PC35:4 15.4(8.7; 22.6) 13(7.4; 15.8) 13.1(7.6; 20.7) 0.031 0.015 0.116 0.644
PC35:5 11.9(6.1; 21) 8.4(4.4; 11.2) 9.2(4.7; 17.6) 0.041 0.024 0.148 0.482
PC36:0 5.3(3.8; 7.7) 4(2.6; 5.4) 4(2.4; 6.7) 0.005 0.003 0.022 0.877
PC36:1 32.7(23.9; 38.3) 22.7(13.4; 30.5) 22.7(17.1; 33.3) <0.001 <0.001 0.002 0.681
PC36:2 106.7(77.7; 124.3) 78.6(51.9; 112.1) 72.1(52.8; 87.3) <0.001 0.001 <0.001 0.509
PC36:3 48.7(44; 68.8) 44.7(29.7; 57.6) 40.7(29.8; 47.2) 0.001 0.09 0.001 0.175
PC36:4 70(39.4; 84.3) 73.7(44; 102) 74.4(47.4; 89.1) 0.682 0.506 0.595 0.932
PC36:5 8.8(5.8; 21.7) 8.8(1.3; 14.9) 9.2(2; 22.7) 0.725 0.491 0.877 0.768
PC37:4 12.7(8.3; 17) 11.4(6; 14.1) 10.8(7.3; 15.3) 0.226 0.235 0.159 0.863
PC37:5 17.3(11; 23.1) 13.5(7.7; 18.6) 14.5(9; 22.5) 0.026 0.018 0.085 0.509
PC37:6 8.6(5.9; 14.9) 6.2(3.4; 8) 7(3.3; 11.6) 0.003 0.002 0.028 0.286
PC38:3 21.6(11.2; 31.9) 23.5(14.4; 38.5) 19.8(10.9; 28.6) 0.157 0.506 0.386 0.091
PC38:4 49.5(28.9; 70.1) 60.7(41.5; 77.5) 60.6(38.4; 72.8) 0.091 0.047 0.29 0.482
PC38:5 19.3(11.8; 26.7) 18.3(8.2; 28.1) 18.9(12.2; 27.7) 0.979 0.95 0.877 0.863
PC38:6 17(12.7; 34.3) 20.7(9.3; 32.4) 18.7(11.1; 34.6) 0.259 0.148 0.815 0.38
PC40:5 5.3(3.3; 7.1) 5.9(3.5; 8.8) 5(2.8; 9.2) 0.387 0.34 0.904 0.343
PC40:6 7.7(5.1; 14.1) 10(5.5; 14.2) 8.5(5.7; 16.1) 0.201 0.104 0.506 0.482
Total LPC 179.2(156.8; 245.2) 136.3(105.3; 181.5) 136.6(110.5; 199.9) <0.001 0.001 0.004 0.623
LPC16:0 90.8(77.4; 121.1) 72.5(52.3; 95.9) 64.1(49.6; 104.2) <0.001 0.001 0.001 0.235
LPC18:0 30.7(26.4; 46.7) 25.6(20; 34.1) 22(15.7; 33.3) 0.001 0.006 0.002 0.098
LPC18:1 21.3(15.4; 28.5) 15.6(10.6; 21.8) 21.2(9.1; 27.6) 0.004 0.004 0.572 0.022
LPC18:2 32.5(25.6; 50.6) 19.5(9.6; 50) 32.1(11.6; 71.6) 0.005 0.005 0.67 0.024
Total PE 16.3(9.9; 26) 11.2(3.4; 23.4) 9.4(5; 17.6) 0.003 0.028 0.003 0.26
PE34:2 1.7(0.9; 3.2) 0.7(0.1; 2.3) 0.6(0.3; 1.8) 0.001 0.003 0.001 0.697
PE35:2 0.3(0.1; 0.5) 0.1(0.03; 0.3) 0.1(0.01; 0.2) <0.001 0.002 0.001 0.768
PE36:4 1.4(0.8; 2.7) 1(0.3; 2.3) 0.9(0.4; 2) 0.07 0.11 0.049 0.721
PE36:3 1.1(0.5; 3.1) 0.6(0.02; 1.3) 0.5(0.2; 0.8) 0.001 0.006 0.002 0.605
PE36:2 4(2.1; 8.5) 1.9(0.4; 5.1) 1.6(0.5; 3.4) <0.001 0.005 0.001 0.248
PE36:1 0.7(0.2; 2) 0.5(0.05; 1.1) 0.4(0.1; 1) 0.041 0.065 0.049 0.391
PE37:5 0.7(0.4; 1.1) 0.4(0.1; 0.7) 0.4(0.2; 1) 0.004 0.003 0.015 0.79
PE37:4 0.4(0.2; 0.8) 0.3(0.02; 0.6) 0.2(0.1; 0.4) 0.014 0.069 0.006 0.623
PE38:6 1.6(0.5; 3.7) 1.6(0.4; 4) 1.1(0.5; 2.9) 0.401 0.857 0.276 0.449
PE38:5 1.1(0.4; 2.6) 0.8(0.3; 2) 0.8(0.4; 1.8) 0.068 0.069 0.065 0.932
PE38:4 2.9(1.9; 6.3) 2.9(1; 5.5) 2.3(1.3; 4.9) 0.055 0.811 0.049 0.079
Total PG 0.3(0.1; 0.8) 0.3(0.1; 0.7) 0.2(0.1; 0.6) 0.099 0.543 0.108 0.117
Total PA n.d. n.d. n.d. - - - e
Total SM 462.9(359.6; 600.4) 385.4(262.7; 547.9) 355.4(275.6; 475.7) 0.002 0.007 0.002 0.523
SM32:1 16.1(12.2; 22.6) 10.7(5.3; 17.8) 10.7(5.3; 16.4) 0.001 0.006 0.001 0.972
SM34:0 4.8(3.1; 6.1) 2.9(0.3; 4.5) 2.7(1.1; 4.2) 0.001 0.003 0.002 0.863
SM34:1 123.6(88.3; 169.2) 99.3(63; 131) 90.6(63.8; 127.6) <0.001 0.002 0.001 0.41
SM34:2 17.8(13; 23.5) 14.6(7.8; 27.8) 13.2(10.8; 20.1) 0.017 0.043 0.012 0.823
SM36:1 23.4(16.4; 33.5) 22(14.8; 32.3) 19.6(11.9; 26.4) 0.345 0.523 0.185 0.623
SM36:2 9.6(7.4; 14.7) 8.8(6.4; 18.8) 8.5(4.9; 13.1) 0.361 0.652 0.231 0.482
SM38:1 23.2(15.8; 28.2) 17.9(12.3; 26.5) 16.9(12.2; 21.7) 0.006 0.04 0.006 0.286
SM39:1 9.2(5.9; 11.7) 6.8(4.3; 11.3) 5.6(4.3; 10.6) 0.005 0.028 0.004 0.499
SM39:2 1.2(0.5; 2.2) 1(0.3; 2.2) 0.9(0.3; 1.8) 0.371 0.435 0.29 0.566
SM40:1 42.6(31.7; 59.8) 33.7(25.9; 47.4) 32(22.2; 44.8) 0.004 0.015 0.004 0.697
SM40:2 28(18.6; 35.8) 23.1(16.4; 36.1) 21(16.9; 37.2) 0.017 0.026 0.022 0.681
SM41:1 22.2(17; 32.9) 19.3(9.7; 28.3) 15.4(13.3; 21.9) 0.001 0.016 0.001 0.314
SM41:2 14(11.6; 23.1) 12(7.3; 17.3) 11.8(8; 20.6) 0.049 0.043 0.065 0.823
SM42:1 39.6(25.8; 53.1) 29.8(19; 42.5) 25.8(19.1; 40.2) 0.005 0.03 0.005 0.327
SM42:2 66.4(51.6; 82.8) 53.6(40.9; 77.6) 55.3(38.4; 79.6) 0.016 0.018 0.026 0.823
SM42:3 22.8(16.7; 33.4) 21.4(15.3; 30.9) 21.5(13.6; 36.8) 0.38 0.324 0.326 0.811
Total Cer/HexCer 12.2(4.9; 20.2) 8.5(2.8; 11.7) 5.4(3.1; 7.4) <0.001 0.013 0.001 0.026
Cer(d18:1/24:0) 2.2(1.4; 4.9) 1.7(1; 2.6) 1.6(0.7; 2.7) 0.041 0.04 0.049 0.932
HexCer(d18:1/22:0) 2.8(0.9; 5) 1.9(0.3; 3) 1.1(0.3; 1.7) <0.001 0.033 0.001 0.01
HexCer(d18:1/23:0) 1.5(0.5; 2.9) 0.8(0.2; 1.7) 0.6(0.2; 1.1) 0.001 0.016 0.001 0.117
(continued on next page)
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Table 3 (continued )
Lipids, mmol/l Healthy subjects (n ¼ 14) CAD (n ¼ 18) AMI (n ¼ 17) Kruskal-Wallis, adj. p values Mann-Whitney U, adj. p values
Median(Min; Max) Median(Min; Max) Median(Min; Max) H vs CAD H vs ACS CAD vs ACS
HexCer(d18:1/24:0) 3.5(1.6; 5.7) 2.2(0.3; 3.8) 1.3(0.7; 2.3) <0.001 0.012 <0.001 0.022
HexCer(d18:1/24:1) 2.2(0.5; 2.9) 1.3(0.5; 2.5) 0.9(0.3; 1.7) 0.004 0.04 0.004 0.185
S1P species
16:1-S1P 0.12(0.09; 0.15) 0.1(0.05; 0.17) 0.1(0.07; 0.13) 0.006 0.014 0.009 0.952
17:1-S1P 0.03(0.02; 0.05) n.d. n.d. - - - -
18:1-S1P 0.55(0.5; 0.81) 0.5(0.38; 0.82) 0.44(0.29; 0.79) 0.011 0.096 0.013 0.11
18:0-S1P 0.05(0.03; 0.07) 0.04(0.03; 0.09) 0.03(0.02; 0.14) 0.198 0.248 0.159 0.523
Sphingoid bases of sphingolipids
C16SO 31.91(14.84; 46.01) 24.97(13.24; 58.88) 21.05(9.48; 48.36) 0.011 0.06 0.004 0.78
C16SA 0.73(0.3; 1.38) 0.63(0.21; 1.26) 0.46(0.24; 1.13) 0.011 0.263 0.006 0.139
C17SO 13.49(8.45; 22.2) 9.65(3.43; 17.94) 9(4.75; 23.95) 0.003 0.016 0.003 0.485
C18SO 145.13(104.41; 203.95) 110.45(64.43; 177.81) 105.05(67.5; 160.82) <0.001 0.002 0.001 0.475
C18SA 4.5(3.11; 6.77) 3.2(1.28; 10.65) 3.02(1.68; 9.48) 0.001 0.012 0.001 0.544
C18SAdiene 52.44(30.66; 78.94) 37.15(24.66; 74.43) 35.66(23.3; 48.22) 0.005 0.043 0.003 0.501
C19SO 3.79(1.66; 7.28) 4.09(1.33; 8.66) 3.12(1.2; 6.81) 0.378 0.932 0.269 0.386
C20SO 0.24(0.14; 0.35) 0.23(0.12; 0.55) 0.21(0.09; 0.36) 0.648 0.628 0.433 0.904
C20SA 0.02(0.01; 0.04) 0.02(0.01; 0.03) 0.02(0.01; 0.04) 0.747 0.911 0.805 0.509
doxSO 0.2(0.15; 0.7) 0.17(0.08; 0.44) 0.19(0.07; 0.78) 0.353 0.248 0.39 0.697
doxSA 0.1(0.07; 0.24) 0.09(0.03; 0.24) 0.07(0.03; 0.33) 0.238 0.208 0.211 0.762
Fig. 1. Volcano plots illustrating the relative differences between healthy subjects and patients with CAD or AMI. The x axis reflects the change (displayed as -log(fold change)
whereas the y axis reflects the significance of change (displayed as -log(adj. p value). p values were calculated by the Mann-Whitney U test. Colored dots represent the individual
groups (blue, GPLs; green, SMs, Cers/HexCers, S1Ps and sphingoid bases; crimson, odd-chain PCs; grey, clinical measures). The p values were adjusted for multiple comparisons
according to the Benjamini-Hochberg procedure. The dashed horizontal line reflects an adj. p < 0.05. (AMI, acute myocardial infarction; CAD, coronary artery disease; H, healthy
subjects; PC, phosphatidylcholine; GPL, glycerophospholipids; SL, sphingolipid). (For interpretation of the references to colour in this figure legend, the reader is referred to the web
version of this article.)
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Fig. 2. Heat map of the spearman correlations between lipid species and cholesterol levels (total, HDL-C, LDL-C) over the entire cohort (N ¼ 49). Red color indicates positive
correlation, blue - negative. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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of total PCs were found in the HDL, approximately 34% were found
in the LDL, 9%were found in the LFF and 2% of PCs were found in the
combined CM/VLDL fractions. Odd and even-chain PC species
showed a similar distribution, with HDL being the major carrier of
these lipids (Fig. 3D). For SM, 56% was found in LDL, 36% in HDL, 5%
in LFF and 2% in CM/VLDL (Fig. 3B, E). 80% of the total LPC species
were found in the LFF, indicating that plasma LPCs are primarily
bond to albumin (Fig. 3C). Small amounts of LPCs were present in
LDL (11%) and HDL (7%). A prominent difference in the lipoprotein
distribution was seen for LPC18:0, when compared to other LPC
species (Fig. 3F). The proportion of LPC18:0was decreased by 20% in
the LFF and increased by 11% in the LDL fraction relative to the
proportion of LPC16:0.4. Discussion
In our study we found significant differences in the lipid profile
between healthy subjects and patients with stable CAD or AMI. Inthe CAD group, plasma concentrations of 45 glycerophospholipids
and sphingolipid species as well as an atypical 16:1-S1P were
significantly lower compared with healthy subjects. Also sphingo-
lipids which are formed on a C17SO, C18SO, C18SA and C18SAdiene
sphingoid base backbone were significantly lower. In the AMI
group, 42 plasma lipid species were significantly reduced
compared to healthy subjects. However, the observed differences
weremore related to CAD than AMI as only minor differences in the
lipid profile were seen between the CAD and AMI group. The
observed differences seem to be independent of statin use as we
did not see a significant effect of a cholesterol lowering therapy
(statins) on glycerophospholipids and sphingolipid levels.
Four odd-chain PC species (PC33:1, PC33:2, PC33:3 and PC35:3),
identified as PC plasmalogens were the most significantly altered
lipids between the healthy and the CAD/AMI group. Reduced
plasmalogen plasma levels were reported previously for hyper-
tensive and obese patients [25,26] as well as for patients with CAD
[9]. Decreased levels of HDL-associated PE plasmalogens were re-
ported in patients with low HDL-C levels and in acute-phase HDL
Fig. 3. Distribution of the total phosphatidylcholines, lysophosphatidylcholines and sphingomyelins (AeC) and of the individual species (DeF) in four major lipoprotein fractions.
Percentages of total phosphatidylcholines (PCs), lysophosphatidylcholines (LPCs) and sphingomyelins (SMs) are expressed as mean (AeC) and the species specific distribution
(mean ± SD) relative to the total lipoprotein content of the individual lipids (DeF). (CM/VLDL, chylomicron/very-low-density lipoprotein, HDL, high-density lipoprotein; LDL, low-
density lipoprotein; LFF, lipoprotein-free fraction).
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PC33:1, PC33:2, PC33:3 and PC35:3 are largely associated with HDL
which partly explains the strong positive correlations of these lipids
with HDL-C as seen by us and others [28].
The physiological functions of plasmalogens are poorly under-
stood. It is unclear whether decreased levels of PC plasmalogens are
due to metabolic effects in CAD and AMI or whether plasmalogens
play an active role in the pathogenesis of CAD. Plasmalogens
possess antioxidant properties due to their ability to scavenge ox-
ygen radicals [29]. Evidence from in vitro studies indicated that
plasmalogens are capable of reducing the oxidation of cell mem-
brane cholesterol, polyunsaturated fatty acids and LDL [30e32].
Thus, low levels of PC plasmalogens may be indicators of increased
oxidative stress which may explain why PC plasmalogens, but not
polyunsaturated PCs, were lower in patients with CAD and AMI.
Our analysis of the sphingoid base profile indicated a reduction
of certain sphingoid bases in patients with CAD and AMI. This is in
line with significantly reduced plasma levels of certain SM species
in patients with CAD and AMI. However, 1-deoxyphingolipids
(doxSA and doxSO), recently found as predictive biomarkers for
the risk to develop type 2 diabetes mellitus [23,33] were notdifferent between healthy controls and patients with CAD or AMI.
Our analysis also revealed the presence of various S1P species,
including typical 18:1-S1P 18:1) and atypical 16:1-S1P, 17:1-S1P
and 18:0 SA1P. Different S1P species were previously reported in
plasma of healthy subjects [34], however, the existence of native
17:1-S1P was here reported for the first time. Among the phos-
phorylated sphingosines, the canonical S1P (18:1) was the most
abundant and found to be lowered in AMI group. In contrast, 16:1-
S1P, was diminished in plasmas of patients with CAD and AMI
compared to healthy subjects. Also other studies reported reduced
S1P levels in plasma and HDL of patients with CAD [22,35] as well
as a significant inverse association of S1P (18:1) and SA1P (18:0)
levels in the HDL-containing fraction of serumwith the occurrence
of ischemic heart disease [36]. In our study we did not see any
significant association between plasma 18:0-SA1P levels and CAD
or AMI. Canonical S1P (18:1) is an important regulator of vascular
function as well as immune and inflammation responses. HDL is the
major carrier of S1P in plasma and HDL bound S1P was reported to
mediate several atheroprotective properties HDL [36], [37]. There-
fore, differences in the concentration and composition of S1Ps in
plasmas of healthy controls and patients with either acute or
Published in final edited form as: Atherosclerosis. 2016 Mar;246:130-40. doi: 10.1016/j.atherosclerosis.2016.01.003chronic cardiovavascular disease may reflect differences in athe-
roprotective plasma functions.
4.1. Limitations
This study was designed as a purely explorative approach to
identify novel lipid signatures in patients with CAD and AMI. Due to
the small group sizes it was not possible to adjust for all potential
confounders such as HDL-C, LDL-C, TG or medications without the
risk of over fitting. This might introduce a bias in particular for the
observed associations with HDL-C which is generally lower in the
CAD patients. However, not all analyzed lipid species showed the
same associationwith HDL-C indicating that changes in total HDL-C
plasma levels are also associated with alterations in the lipid
composition of HDL. Further lipid species might show significant
changes when validating the study in a bigger cohort.
5. Conclusions and perspectives
In conclusion, we found that plasma levels of various glycer-
ophospholipid and sphingolipid species are reduced in patients
with CAD and AMI. Among them, PC33:1, PC33:2, PC33:3 and
PC35:3, identified as plasmalogens PC(P-18:0/18:2), PC(P-18:0/
16:0), PC(P-16:0/18:1) and PC(P-16:0/18:2), were the most signifi-
cantly altered species in the plasma of patients with CAD. Reduced
plasmalogen levels might be indicators for oxidative stress as it is
typically seen in patients with CAD. We also found that these PC
species are preferentially localized in HDL particles and correlate
positively with HDL-C levels. However, as this was an explorative
study to find novel lipid signatures the observed associations need
to be validated in a larger cohort which allows to adjust for more
potential confounders in multivariate statistical tests.
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